Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recifercept in Children with Achondroplasia
NCT04638153Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Dec 2020
- Primary completion
- Jan 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 8
01
Overview
A Phase 2 trial of recifercept in achondroplasia (ACH), sponsored by Pfizer. Started Dec 2020; status: terminated.
02
Drugs
recifercept
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT04638153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04638153.